-
support exploration of novel therapies. Conduct in vivo studies to evaluate and establish efficacy, PK/PD relationship, combination strategy, biomarker identification and analysis. Perform ancillary in
-
first in human (FIH) through proof of concept (PoC) studies, including proof of mechanism (PoM) and early signals of efficacy (ESoE) studies in a given therapeutic area. The primary therapeutic areas
-
new milestones and help patients across the globe. How You Will Achieve It Set objectives for and manage multiple projects within a division. Ensure work is inspection ready and act as a key data
-
disease states to optimize doses, dosage regimens and study designs throughout all phases (first-in-human through post-approval) of clinical drug development. With guidance, identify opportunities where
-
or original ideas and lead business unit projects of a complex nature. Develop mid-term plans that impact the achievement of business unit results. Act as an enterprise leader in Quality, influencing and
-
to contribute to selection of targets for progression from chemical/biologic synthesis to testing in human. Leads the creation of the clinical development plan from pre-clinical stages through to proof of concept
-
other leaders within the Oncology Research Unit (ORU) and in Early Clinical Development to advance innovative development candidates. The CI Head will act as a cancer immunology subject matter expert
-
Location Assignment:On Premise Relocation support available Relocation assistance may be available based on business needs and/or eligibility. Sunshine Act Pfizer reports payments and other transfers
-
eligibility. Sunshine Act Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and
-
eligibility. Sunshine Act Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and